Reference
Tang X, et al. MVP combined with FC as lymphocyte-depleting chemotherapy before car-t treatment can reduce the incidence of severe cytokine release syndrome for relapsed/refractory all patients with high tumour burden. Blood 130 (Suppl. 1): Dec 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/5041?sso-checked=true [abstract] - China
Rights and permissions
About this article
Cite this article
Anti CD19 CAR transduced T cells. Reactions Weekly 1695, 36 (2018). https://doi.org/10.1007/s40278-018-43864-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43864-y